Amgen Inc at Bank of America Merrill Lynch Health Care Conference Transcript
Good morning, everyone. Welcome to Day 2 of the Bank of America Merrill Lynch Global Healthcare Conference. My name is Ying Huang, and I'm senior analyst covering U.S. large cap biotech here at BofA. We're very pleased to introduce our next company, Amgen. Well, the fire's up already. So we're going to use the fireside chat format. We have the EVP and CFO David Meline; and also Arvind Sood, Head of Investor Relations from Amgen with us. So while the fire's up, I guess.
Thank you, Ying. Yes. So we always use this for fireside chat. It sort of sets the -- again, the relax mood in the room, calms everybody down right? Yes. So I'll give a few comments of introduction, and then we can go to Q&A.
So I'm David Meline with Amgen. I think those of you who know us recognize that we've established a very good and stable track record of execution over recent years. The first quarter was no exception of that. We had mid-single
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
